Revisiting Anti-TNF 20 Years Later

This Anti-TNF webcast will review the current rationale, safety, effects, and opportunities of Anti-TNF opposed to 20 years ago. The webcast features Dr. John Looney, University of Rochester.

The video was produced by the Cleveland Clinic Foundation Center for Continuing Education and the R.J. Fasenmyer Center for Clinical Immunology.

[nikolaospeterson]

Interesting. I am somewhat familiar with the cytokines, and TNFs in relation to a condition  have and I am familiar with Remicade (infliximab) as I have IBD (Crohn’s). I
used to be treated with anti alpha TNF infusions, but now with vedolizumab
(Entyvio). Now whether this has also been applied to RA patirnts, I do not
know. My question is how does the TNF distinguish whether joints or small
intestines (or digestive tracts in general, and more specifically the ileum
and/or caecum? What is the mechanism that distinguishes rheumatoid arthritis
from inflammatory bowel disease. Different aisles or genetics? Thanks.